Table 1.

Summary of the breast tumor molecular subtypes

Intrinsic subtype	IHC status	Grade	Outcome	PrevalenceΔ
Luminal A*	[ER+|PR+] HER2-KI67-	1|2	Good	23.7% [p1] [10]
Luminal B*	[ER+|PR+] HER2-KI67+	2|3	Intermediate	38.8% [p1] [10]
	[ER+|PR+] HER2+KI67+		|Poor	14% [p1] [10]
HER2 over-expression*	[ER-PR-] HER2+	2|3	Poor	11.2% [p1] [10]
Basal*	[ER-PR-] HER2-, basal marker+	3	Poor	12.3% [p1] [10]
Normal-like	[ER+|PR+] HER2-KI67-	1|2|3	Intermediate	7.8% [p2] [15]

^*Subtypes with detailed expression patterns and clinical implications discussed in the text, which take the majority of the breast tumor cases and are most commonly referred to.

^ΔThe prevalence of each subtype is taken from the publication indicated in the square bracket.